At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 107 enrolled
Drug / intervention
pazopanib and pemetrexed +1 moredrug
Likely dose
pazopanib and pemetrexed 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Multicentre, Randomised Phase II Study of Pazopanib in Combination With Pemetrexed in First-line Treatment of Subjects With Predominantly Non-squamous Cell Stage IIIBwet/IV Non-small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating pazopanib and pemetrexed and pemetrexed and cisplatin for Lung Cancer, Non-Small Cell. Completed, enrolled 107 participants across 2 sites in 2 countries.
Detailed Summary
The main purpose of this study is to determine whether the combination of pazopanib and pemetrexed is safe and effective in the treatment of advanced non-small cell lung cancer (NSCLC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer, Non-Small Cell
CountriesDenmark, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 2009
Enrollment StartJul 2009
Primary CompletionMar 2011
TodayJul 2026
First PostedMar 30, 2009
Enrollment StartJul 1, 2009
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 17.3 years ago
Interventions
pazopanib and pemetrexeddrug
oral pazopanib 600 mg once daily and pemetrexed intravenous (IV) 500mg/m\^2 once every 3 weeks, then pazopanib 800 mg once daily
pemetrexed and cisplatindrug
pemetrexed IV 500 mg/m\^2 and cisplatin IV 75 mg/m\^2 once every 3 weeks